139 related articles for article (PubMed ID: 37716872)
21. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.
Shah BD; Cassaday RD; Park JH; Houot R; Oluwole OO; Logan AC; Boissel N; Leguay T; Bishop MR; Topp MS; Tzachanis D; O'Dwyer KM; Arellano ML; Lin Y; Baer MR; Schiller GJ; Subklewe M; Abedi M; Minnema MC; Wierda WG; DeAngelo DJ; Stiff PJ; Jeyakumar D; Mao D; Adhikary S; Zhou L; Schuberth PC; Damico Khalid R; Ghobadia A
J Immunother Cancer; 2023 Aug; 11(8):. PubMed ID: 37648261
[TBL] [Abstract][Full Text] [Related]
22. Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma.
Weisel K; Martin T; Krishnan A; Jagannath S; Londhe A; Nair S; Diels J; Vogel M; Schecter JM; Banerjee A; Berdeja JG; Nesheiwat T; Garrett A; Qi K; Valluri S; Usmani SZ; Yong K
Clin Drug Investig; 2022 Jan; 42(1):29-41. PubMed ID: 34822128
[TBL] [Abstract][Full Text] [Related]
23. Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German Registry.
Merz M; Goldschmidt H; Hari P; Agha M; Diels J; Ghilotti F; Perualila NJ; Cabrieto J; Haefliger B; Sliwka H; Schecter JM; Jackson CC; Olyslager Y; Akram M; Nesheiwat T; Kellermann L; Jagannath S
Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885106
[TBL] [Abstract][Full Text] [Related]
24. Meta-analysis of ciltacabtagene autoleucel versus physician's choice therapy for the treatment of patients with relapsed or refractory multiple myeloma.
Costa LJ; Hari P; Berdeja JG; De Stefano V; Gay F; Hooper B; Bartlett M; Haltner A; Rosta E; Kumar S; Martin T; Mateos MV; Moreau P; Usmani SZ; Olyslager Y; Schecter JM; Roccia T; Garrett A; Lee S; Nesheiwat T; Pacaud L; Zhou C; Samjoo IA; Lin Y; Diels J; Valluri S; Weisel K
Curr Med Res Opin; 2022 Oct; 38(10):1759-1767. PubMed ID: 35815818
[No Abstract] [Full Text] [Related]
25. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China.
Wu W; Ding S; Mingming Z; Yuping Z; Sun X; Zhao Z; Yang Y; Hu Y; Dong H
J Med Econ; 2023; 26(1):701-709. PubMed ID: 37145966
[TBL] [Abstract][Full Text] [Related]
26. Population-based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma.
Wu LS; Su Y; Li C; Zhou W; Jackson CC; Sun YN; Zhou H
Clin Transl Sci; 2022 Dec; 15(12):3000-3011. PubMed ID: 36204820
[TBL] [Abstract][Full Text] [Related]
27. Chimeric Antigen Receptor T Cell Therapy for Myeloma: Where Are We Now and What Is Needed to Move Chimeric Antigen Receptor T Cells Forward to Earlier Lines of Therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Anderson LD; Dhakal B; Jain T; Oluwole OO; Shah GL; Sidana S; Perales MA; Pasquini MC
Transplant Cell Ther; 2024 Jan; 30(1):17-37. PubMed ID: 37913909
[TBL] [Abstract][Full Text] [Related]
28. CAR T-Cell Therapy for Multiple Myeloma: A Clinical Practice-Oriented Review.
Sadek NL; Costa BA; Nath K; Mailankody S
Clin Pharmacol Ther; 2023 Dec; 114(6):1184-1195. PubMed ID: 37750399
[TBL] [Abstract][Full Text] [Related]
29. Ciltacabtagene autoleucel for the treatment of multiple myeloma.
Holstein SA
Drugs Today (Barc); 2023 Jan; 59(1):1-16. PubMed ID: 36811414
[TBL] [Abstract][Full Text] [Related]
30. The preclinical discovery and clinical development of ciltacabtagene autoleucel (Cilta-cel) for the treatment of multiple myeloma.
Strassl I; Podar K
Expert Opin Drug Discov; 2024 Apr; 19(4):377-391. PubMed ID: 38369760
[TBL] [Abstract][Full Text] [Related]
31. Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma.
Yamamoto C; Minakata D; Yokoyama D; Furuki S; Noguchi A; Koyama S; Oyama T; Murahashi R; Nakashima H; Ikeda T; Kawaguchi SI; Hyodo K; Toda Y; Ito S; Nagayama T; Umino K; Morita K; Ashizawa M; Ueda M; Hatano K; Sato K; Ohmine K; Fujiwara SI; Kanda Y
Transplant Cell Ther; 2024 Jan; 30(1):118.e1-118.e15. PubMed ID: 37802181
[TBL] [Abstract][Full Text] [Related]
32. SOHO State of the Art Updates and Next Questions: Will CAR-T Replace ASCT in NDMM.
Jurgens E; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 May; 24(5):277-284. PubMed ID: 38331676
[TBL] [Abstract][Full Text] [Related]
33. Long-Term Follow-up of CALGB (Alliance) 100001: Autologous Followed by Nonmyeloablative Allogeneic Transplant for Multiple Myeloma.
Holstein SA; Suman VJ; Owzar K; Santo K; Benson DM; Shea TC; Martin T; Silverman M; Isola L; Vij R; Cheson BD; Linker C; Anderson KC; Richardson PG; McCarthy PL
Biol Blood Marrow Transplant; 2020 Aug; 26(8):1414-1424. PubMed ID: 32325171
[TBL] [Abstract][Full Text] [Related]
34. Extrapolation of Survival Data Using a Bayesian Approach: A Case Study Leveraging External Data from Cilta-Cel Therapy in Multiple Myeloma.
Palmer S; Lin Y; Martin TG; Jagannath S; Jakubowiak A; Usmani SZ; Buyukkaramikli N; Phelps H; Slowik R; Pan F; Valluri S; Pacaud L; Jackson G
Oncol Ther; 2023 Sep; 11(3):313-326. PubMed ID: 37270762
[TBL] [Abstract][Full Text] [Related]
35. Cilta-cel OK'd for Multiple Myeloma.
Cancer Discov; 2022 May; 12(5):1176. PubMed ID: 35491644
[TBL] [Abstract][Full Text] [Related]
36. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.
Rodriguez-Otero P; Ailawadhi S; Arnulf B; Patel K; Cavo M; Nooka AK; Manier S; Callander N; Costa LJ; Vij R; Bahlis NJ; Moreau P; Solomon SR; Delforge M; Berdeja J; Truppel-Hartmann A; Yang Z; Favre-Kontula L; Wu F; Piasecki J; Cook M; Giralt S
N Engl J Med; 2023 Mar; 388(11):1002-1014. PubMed ID: 36762851
[TBL] [Abstract][Full Text] [Related]
37. Humanized Anti-CD19 CAR-T Cell Therapy and Sequential Allogeneic Hematopoietic Stem Cell Transplantation Achieved Long-Term Survival in Refractory and Relapsed B Lymphocytic Leukemia: A Retrospective Study of CAR-T Cell Therapy.
Chen W; Ma Y; Shen Z; Chen H; Ma R; Yan D; Shi M; Wang X; Song X; Sun C; Cao J; Cheng H; Zhu F; Sun H; Li D; Li Z; Zheng J; Xu K; Sang W
Front Immunol; 2021; 12():755549. PubMed ID: 34777367
[TBL] [Abstract][Full Text] [Related]
38. Real-world experience of commercial relmacabtagene autoleucel (relma-cel) for relapsed/refractory central nervous system lymphoma: a multicenter retrospective analysis of patients in China.
Yu W; Huang L; Mei H; Li Y; Niu T; Zou D; Liu Y; Zhang H; Liu P; Wu J; Wang Z; Li H; Cai Q; Mi JQ
J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38802271
[TBL] [Abstract][Full Text] [Related]
39. Serum soluble BCMA can be used to monitor relapse of multiple myeloma patients after chimeric antigen receptor T-cell immunotherapy.
Shen Y; Liu J; Wang B; Zhang Y; Xu Y; Wang X; Jia Y; Meng X; Wang X; Fan X; He A; Zhao W
Curr Res Transl Med; 2023; 71(2):103378. PubMed ID: 36720180
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
